The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma – a pilot study

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2012-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2036.2011.04896.xPMID 22032637
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pathophysiology of Portal Hypertension

  2015cited by this paper
• Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis

  2011cited by this paper
• Clinical characteristics of patients with hepatocellular carcinoma in Austria – is there a need for a structured screening program?

  2011cited by this paper
• Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib

  2011influential reference
• Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection.

  2011cited by this paper
• Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.

  2010cited by this paper
• New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis.

  2010cited by this paper
• Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.

  2009cited by this paper
• Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats.

  2009cited by this paper
• Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats

  2009cited by this paper
• Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis

  2009cited by this paper
• Acute Hepatitis in a Patient With Cirrhosis and Hepatocellular Carcinoma Treated With Sorafenib

  2009cited by this paper
• Sorafenib-Induced Liver Failure

  2008cited by this paper
• Mechanisms of extrahepatic vasodilation in portal hypertension

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Platelet-derived growth factor isoform expression in carbon tetrachloride-induced chronic liver injury

  2008cited by this paper
• Review article: the modern management of portal hypertension – primary and secondary prophylaxis of variceal bleeding in cirrhotic patients

  2008cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Measurement of portal pressure and its role in the management of chronic liver disease.

  2006cited by this paper
• Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis

  2006cited by this paper
• The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule

  2006cited by this paper
• Angiogenesis as a therapeutic target

  2005cited by this paper
• Portal hypertension: from bedside to bench.

  2005influential reference
• Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats.

  2005cited by this paper
• Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension.

  2005cited by this paper
• Fasudil hydrochloride hydrate, a Rho‐kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells

  2005cited by this paper
• Austrian Consensus on the Definition and Treatment of Portal Hypertension and its Complications

  2005cited by this paper
• Erratum: Liver fibrosis (Journal of Clinical Investigation (2005) 115 (209-218) DOI:10.1172/JCI200524282)

  2005cited by this paper
• Liver fibrosis.

  2005cited by this paper
• The hepatic venous pressure gradient: Anything worth doing should be done right

  2004cited by this paper
• Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice.

  2004cited by this paper
• Liver fibrosis

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• Involvement of Rho/Rho kinase pathway in regulation of apoptosis in rat hepatic stellate cells.

  2003cited by this paper
• Vascular mediators in the injured liver

  2003cited by this paper
• Randomized comparison of long‐term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis

  2002cited by this paper
• Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

  2001cited by this paper
• Complications of cirrhosis. I. Portal hypertension.

  2000cited by this paper
• Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension

  2000cited by this paper
• Molecular Regulation of Hepatic Fibrosis, an Integrated Cellular Response to Tissue Injury*

  2000cited by this paper
• Carvedilol, a new nonselective beta‐blocker with intrinsic anti‐alpha1‐adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis

  1999cited by this paper
• Blood vessel formation: what is its molecular basis?

  1996cited by this paper
• Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis.

  1995cited by this paper
• Pathophysiology of portal hypertension.

  1992cited by this paper

• Translating Fibrosis to Malignancy: Biomarkers and Therapeutic Opportunities in Liver Fibrosis and Hepatocellular Carcinoma

  2026cites this paper
• Recompensation in Cirrhosis: Biomarkers and Strategies

  2025cites this paper
• Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction

  2025cites this paper
• Myelofibrosis-associated extramedullary hematopoiesis: Insights into hepatic, pulmonary, and thrombotic complications.

  2025cites this paper
• Identifying the Optimal Treatment for Patients with Hepatocellular Carcinoma and Clinically Significant Portal Hypertension: A Multicenter Propensity Score-Weighted Analysis

  2025cites this paper
• Pathophysiology and therapeutic options for cirrhotic portal hypertension.

  2024cites this paper
• Role of the portal system in liver regeneration: From molecular mechanisms to clinical management

  2024cites this paper
• Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives

  2024cites this paper
• Role of Hydrogen Sulfide and Hypoxia in Hepatic Angiogenesis of Portal Hypertension

  2023cites this paper
• Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy

  2023cites this paper
• Recent advances in promising drugs for primary prevention of gastroesophageal variceal bleeding with cirrhotic portal hypertension.

  2023cites this paper
• Recent Approaches in Portal Hypertension Involving Risk Stratification and Medical Management.

  2023cites this paper
• Portal hypertension in patients with hepatocellular carcinoma and immunotherapy: prognostic relevance of CT-morphologic estimates

  2023cites this paper
• The Baveno VII concept of cirrhosis recompensation.

  2023cites this paper
• Management of upper gastrointestinal bleeding in advanced hepatocellular carcinoma with portal hypertension and variceal bleeding during receiving tyrosine kinase inhibitors therapy: Beyond and known frontiers

  2023cites this paper
• Current and investigational drugs in early clinical development for portal hypertension

  2022cites this paper
• Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications

  2022cites this paper
• Investigational drugs in early clinical development for portal hypertension

  2022cites this paper
• Response to 'Letter to the Editor' written by Dr. Isabelle Ollivier-Hourmand.

  2022cites this paper
• Pathophysiology and Management of Variceal Bleeding

  2021cites this paper
• Regression of portal hypertension: underlying mechanisms and therapeutic strategies

  2021cites this paper
• Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis

  2021cites this paper
• Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses…

  2021cites this paper
• Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.

  2021cites this paper
• Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib

  2021cites this paper
• Die Effekte des Multikinase-Inhibitors Regorafenib auf die zirrhotische und nicht-zirrhotische portale Hypertension im Rattenmodell

  2020cites this paper
• Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma

  2020cites this paper
• Primary prevention of bleeding from esophageal varices in patients with liver cirrhosis: An update and review of the literature

  2020cites this paper
• Nonalcoholic fatty liver disease and portal hypertension.

  2020cites this paper
• Novel therapeutics for portal hypertension and fibrosis in chronic liver disease.

  2020cites this paper
• REVIEW STUDY: MANAGEMENT OF LIVER CIRRHOSIS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

  2020cites this paper
• Measurement of the Hepatic Venous Pressure Gradient (HVPG)

  2020cites this paper
• Nanoparticles and their Biomedical Applications

  2020cites this paper
• Nanomedicine for Hepatic Fibrosis

  2020cites this paper
• Novel targeted therapies for the management of liver fibrosis

  2020cites this paper
• Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma

  2019cites this paper
• Novel Targets and Drug Development in Portal Hypertension

  2019cites this paper
• ORGAN FIBROSIS AT A GLANCE

  2019cites this paper
• Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis

  2019cites this paper
• Relative Efficacy of Systemic Treatments for Patients with Advanced Hepatocellular Carcinoma According to Viral Status: A Systematic Review and Network Meta-Analysis

  2019cites this paper
• Relative Efficacy of Systemic Treatments for Patients with Advanced Hepatocellular Carcinoma According to Viral Status : A

  2019cites this paper
• Future Pharmacological Therapies of Portal Hypertension

  2019cites this paper
• Vascular Targets for the Treatment of Portal Hypertension

  2019cites this paper
• Insights into the success and failure of systemic therapy for hepatocellular carcinoma

  2019cites this paper
• Pharmacologic Management of Portal Hypertension.

  2019cites this paper
• Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information.

  2019cites this paper
• Pericytes in the Gut.

  2019cites this paper
• Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.

  2018cites this paper
• Involvement of platelet‐derived growth factor ligands and receptors in tumorigenesis

  2018cites this paper
• Review article: systemic treatment of hepatocellular carcinoma

  2018cites this paper
• Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats.

  2018cites this paper
• Antiangiogenic therapy for portal hypertension in liver cirrhosis: Current progress and perspectives

  2018cites this paper
• Advances in therapeutic options for portal hypertension

  2018cites this paper
• Перспективы антиангиогенной терапии портальной гипертензии при циррозе печени

  2018cites this paper
• The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension

  2018cites this paper
• Liver Cancer Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma

  2018cites this paper
• Hepatic microcirculation and mechanisms of portal hypertension

  2018cites this paper
• Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development

  2018cites this paper
• Association of platelet count and mean platelet volume with overall survival in patients with cirrhosis and unresectable hepatocellular carcinoma

  2018cites this paper
• Prospects of Antiangiogenic Therapy for Portal Hypertension in Liver Cirrhosis

  2018cites this paper
• Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon

  2018cites this paper
• Involvement of PDGF ligands and receptors in tumorigenesis

  2017cites this paper
• Chapter 35 – Gastroesophageal Varices

  2017cites this paper
• Sorafenib: A potential therapeutic drug for hepatic fibrosis and its outcomes.

  2017cites this paper
• Use of inhibitors of the renin angiotensin system is associated with longer survival in patients with hepatocellular carcinoma

  2017cites this paper
• An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma

  2017cites this paper
• Novel treatment options for portal hypertension

  2017cites this paper
• [Aspects of pathogenetc pharmacotherapy for portal hypertension in liver cirrhosis].

  2016cites this paper
• Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?

  2016cites this paper
• New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials

  2016cites this paper
• Clinical Advancements in the Targeted Therapies against Liver Fibrosis

  2016cites this paper
• Angiogenesis and portal-systemic collaterals in portal hypertension.

  2016cites this paper
• Emerging therapies for portal hypertension in cirrhosis

  2016cites this paper
• Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib

  2016cites this paper
• Portal hypertension: Etiology, evaluation, and management.

  2016cites this paper
• Pathogenesis of Portal Hypertension: Extrahepatic Mechanisms

  2016cites this paper
• Impact of Treatment of Non-bleeding Complications of Cirrhosis on the Risk of Variceal Bleeding

  2016cites this paper
• Cancer and liver cirrhosis: implications on prognosis and management

  2016cites this paper
• Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis.

  2015cites this paper
• Lesiones vasculares gástricas en la cirrosis: gastropatía y ectasia vascular antral

  2015cites this paper
• Gastroenteropatía por hipertensión portal: prevalencia y factores predictivos, utilidad de los métodos diagnósticos y determinación de los niveles plasmáticos de factores angiogénicos

  2015cites this paper
• Molecular pathophysiology of portal hypertension

  2015cites this paper
• Hagen-Poiseuille's law: The link between cirrhosis, liver stiffness, portal hypertension and hepatic decompensation.

  2015cites this paper
• [Gastric vascular lesions in cirrhosis: gastropathy and antral vascular ectasia].

  2015cites this paper
• Inflammation and portal hypertension - the undiscovered country.

  2014cites this paper
• Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats

  2014cites this paper
• Disruption of negative feedback loop between vasohibin‐1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats

  2014cites this paper
• Targeting the PDGF Signaling Pathway in the Treatment of Non-Malignant Diseases

  2014cites this paper
• Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law

  2014cites this paper
• Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions.

  2014cites this paper
• Future therapy of portal hypertension in liver cirrhosis – a guess

  2014cites this paper
• Pharmacologic management of portal hypertension.

  2014cites this paper
• Letter: the reversal of liver cirrhosis – what we know and what we need to know – authors’ reply

  2013cites this paper
• Letter: the antiviral activity of sorafenib in patients with hepatitis C‐related hepatocellular carcinoma

  2013cites this paper
• Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case‐control study

  2013cites this paper
• Sorafenib in the Continuum of Care for Hepatocellular Carcinoma: Challenges in Defining Optimal Practice

  2013cites this paper
• Vasoactive Substances and Inflammatory Factors in Progression of Liver Cirrhosis with Portal Hypertension

  2013cites this paper
• The anti‐viral effect of sorafenib in hepatitis C‐related hepatocellular carcinoma

  2013cites this paper
• Letter: sorafenib in portal hypertension

  2012cites this paper
• Letter: sorafenib in portal hypertension – authors' reply

  2012cites this paper